DC-SIREN
30.1.2024 13:08:28 CET | Business Wire | Press release
Siren, the company that provides an all-in-one investigation platform to Police and Sheriff's Departments, Intelligence and Law Enforcement Agencies, Fusion Centers and High Intensity Drug Trafficking Areas programs (HIDTAs) has launched a new AI-Powered search with mobile access as part of its latest release and its Siren for Law Enforcement product bundle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240125060576/en/
New Simplified Search (Photo: Business Wire)
Siren provides a complete suite of investigation tools for contemporary challenges such as police vetting, “Smash and Grab” violence, VIP protection, trafficking, supply chain rime and maritime security.
Siren connects local classified information with external vendor data as well as data available from public sources (OSINT), to identify patterns, actors and events. Siren is now available on mobile devices to provide an additional layer of safety for front line officers.
The new AI-driven search dramatically reduces the complexity in connecting disparate intelligence. Complex links can be made by anyone from any department, using a basic language based search and without the need for analytical skills. According to Siren’s research, it takes at least six months for a new analyst to become productive. The simple interface naturally distributes the workload.
Siren makes it possible for front-line officers to background check suspects, companies and properties from a mobile device prior to criminal interactions and site raids. The new Siren innovation offers an extra layer of security, reducing the risk of unexpected dangers and providing fast actionable leads.
"Simple is hard and that’s what we have achieved with Siren 14.” said John Randles, CEO of Siren. “Siren can now provide complex connected intelligence to Command Staff and Uniformed Police without data science training. It’s a simple search just like using the internet or shopping online.” he concluded.
“The new ability to search in Siren will push the control of basic investigations and safety checks back out into the hands of those who need it most.” said Siren customer, Kathleen Miles, Head of Client Relations, and Co-Founder of Ex Arca, an open-source research firm. “Siren mobile means that intelligence teams can focus on the work they are trained to do.” she added.
"Siren is now accessible to the whole department which is a complete game changer. Democratising intelligence like this is a change not seen in twenty years of technology." commented Bob Griffin, Chairman of Siren.
About Siren
Siren is an all-in-one investigation platform used by law enforcement, intelligence agencies and corporations to safeguard people, assets and networks. Siren links data from open source, vendors and classified sources to surface unconnected intelligence. Siren’s patented technology is uniquely search-based providing a simple interface and advanced reporting for investigations at Enterprise speed and scale.
In November 2023, Siren achieved 9th in Deloitte’s Technology Fast 50. Siren received €12 million funding in 2023 and was named a Gartner Cool Vendor in 2020. For more information, visit www.siren.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240125060576/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
